Literature DB >> 29040028

Elaboration in type, primary structure, and bioactivity of polysaccharides derived from mollusks.

Ling Chong Wang1,2, Liu Qing Di1, Jun Song Li1, Li Hong Hu1,3, Jian Ming Cheng1,2, Hao Wu1,2.   

Abstract

Over the past decades, numerous Mollusca species have received more attention in development and utilization as valuable bio-resources. Many efforts have been focused on investigating mollusk polysaccharides because of their rich content, ease of extraction, diversified sorts, specific structure, various biofunctions and potent activities. To date, many mollusks, especially species of gastropods, bivalves, or cephalopods, have been reported containing polysaccharide compounds in tissues with abundant amount, and most of polysaccharides are obtainable through combining techniques of extraction, separation and purification. The polysaccharides isolated from mollusks appeared with various structural and physicochemical characteristics, ranged from neutral polysaccharides and sulfated polysaccharides, to GAGs series (including Hep/HS, CS/DS, HA and similarities), even to heterogeneous glycan with high molecular weight. This review article provides comprehensive knowledge of recent researches on type classification, tissue origins and possible biofunctions of various polysaccharides from mollusks. The highlights were placed in structure variation including molecular weight, sulfation pattern, linkages and monomer compositions for repeating unit, and primary molecular construction of the mollusks polysaccharides. In addition, this article covers general information on exhibition of mollusks polysaccharide extracts or preparations in the various bioactivities, such as anticoagulant, antiatherogenic, antioxidant, immunomodulatory, antivirus and antitumor activities, which would reveal their possible potentials in medical application. Furthermore, the article presents a brief overview on several challenges and future scope in this field.

Entities:  

Keywords:  Bioactivities; Glycosaminoglycan; Mollusks; Polysaccharide; Structure diversity

Mesh:

Substances:

Year:  2017        PMID: 29040028     DOI: 10.1080/10408398.2017.1392289

Source DB:  PubMed          Journal:  Crit Rev Food Sci Nutr        ISSN: 1040-8398            Impact factor:   11.176


  6 in total

1.  Distribution analysis of polysaccharides comprised of uronic acid-hexose/hexosamine repeating units in various shellfish species.

Authors:  Chunyang Cao; Shuang Song; Bin Liu; Chunqing Ai; Zhenjun Zhu; Lilong Wang; Sufeng Wu
Journal:  Glycoconj J       Date:  2018-10-15       Impact factor: 2.916

Review 2.  Complementary Methods to Improve the Depuration of Bivalves: A Review.

Authors:  Antía Martinez-Albores; Aroa Lopez-Santamarina; José Antonio Rodriguez; Israel Samuel Ibarra; Alicia Del Carmen Mondragón; Jose Manuel Miranda; Alexandre Lamas; Alberto Cepeda
Journal:  Foods       Date:  2020-01-24

3.  Immunomodulatory Effects of a Low-Molecular Weight Polysaccharide from Enteromorpha prolifera on RAW 264.7 Macrophages and Cyclophosphamide- Induced Immunosuppression Mouse Models.

Authors:  Yingjuan Liu; Xiaolin Wu; Weihua Jin; Yunliang Guo
Journal:  Mar Drugs       Date:  2020-06-28       Impact factor: 5.118

Review 4.  A review on shellfish polysaccharides: Extraction, characterization and amelioration of metabolic syndrome.

Authors:  Xingwei Xiang; Qihong Jiang; Hongshun Yang; Xuxia Zhou; Yufeng Chen; Hui Chen; Shulai Liu; Lin Chen
Journal:  Front Nutr       Date:  2022-09-13

5.  Isolation and Characterization of a Heparin-Like Compound with Potent Anticoagulant and Fibrinolytic Activity from the Clam Coelomactra antiquata.

Authors:  ZhenXing Du; XueJing Jia; Jing Chen; SiYi Zhou; JianPing Chen; XiaoFei Liu; XiaoHuang Cao; SaiYi Zhong; PengZhi Hong
Journal:  Mar Drugs       Date:  2019-12-19       Impact factor: 5.118

6.  Anti-HBV Activities of Polysaccharides from Thais clavigera (Küster) by In Vitro and In Vivo Study.

Authors:  Fei Tang; Guanghua Huang; Liping Lin; Hong Yin; Lili Shao; Ruian Xu; Xiuling Cui
Journal:  Mar Drugs       Date:  2021-03-30       Impact factor: 5.118

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.